Royalty Pharma.
biopharmaceutical company based in New York City
- Reports this week
- 0
- Active events
- 0
- Connections
- 62
What's happening
Earlier this month
-
FDA granted approvals for RASONQUE and WELTRUZA on November 4, 2026.Some support1 report
-
Royalty Pharma acquired a royalty interest in Amgen's drug Imdelltra.Well supported9 reports1 development inside
-
Royalty Pharma is investing in drug makers and developers to diversify its portfolio in the biotech sector.Some support1 report
-
Royalty Pharma and Aditxt, two healthcare companies, are currently being compared.Some support1 report
One to three months ago
-
Multiple investment firms acquired, sold, and increased stakes in Royalty Pharma on October 13, 2026.Some support1 report
-
Citigroup, Morgan Stanley, and TD Cowen have raised their price targets and upgraded ratings for Royalty Pharma, with filings made public via the SEC.Some support4 reports
-
Bank of America raised holdings in Royalty Pharma, and Royalty Pharma filed a transaction with the SEC.Some support1 report
-
Visteon filed transaction details with the SEC and traded on the Nasdaq stock exchange on June 6, 2026.Some support6 reports
-
Royalty Pharma's CFO discussed policy risks affecting company strategy, and the company hired an executive from Goldman Sachs for its China team.Some support1 report
-
Pablo Legorreta was named the founder and CEO of Royalty Pharma, which provides funding in exchange for royalty rights.Well supported9 reports
-
Royalty Pharma outperformed the market so far this year, based on data from August 6, 2025.Some support1 report1 development inside
-
Novartis' trial results are impacting Royalty Pharma's investment decisions.Some support2 reports
-
Stock trading activity for multiple companies, including Royalty Pharma, TTM Technologies, Trane Technologies, and others, was reported on the Nasdaq exchange on August 30, 2026.Some support1 report
Gone quiet
No new reports in 90+ days-
Bank of America reissued a buy rating and Morgan Stanley lifted the price target for Royalty Pharma.Some support1 report
-
Royalty Pharma acquired a royalty interest in AstraZeneca's cliramitug.Some support4 reports
-
Royalty Pharma filed a prospectus with the Securities and Exchange Commission on September 3, 2025.Well supported5 reports
-
Royalty Pharma is headquartered in New York City and opened its first Asia-Pacific base in Hong Kong, while Kenneth Sun moved from Morgan Stanley to the company.Some support1 report
-
Trump pledged to unleash American oil and gas, involving Royalty Pharma.Some support1 report
-
Kadant, News Corp, Cencora, and Royalty Pharma were identified as high-quality stocks operating in the pharmaceutical industry.Speculative1 report
-
Buffett described how share prices do not reflect business value, discussing the role of TSR and dividends in the context of Royalty Pharma.Speculative2 reports
-
Royalty Pharma enhanced its governance structure following an acquisition by an external manager.Some support1 report
-
Morgan Stanley raised its price target for Royalty Pharma, noting regulatory uncertainty and the impact of tariffs.Some support1 report
-
Peter Lynch's advice contrasts with the focus on profitable companies regarding Royalty Pharma.Some support1 report
-
Revolution Medicines received Breakthrough Therapy Designation and entered into a major funding agreement, while activating international clinical trials in Europe and Japan.Some support4 reports
-
Royalty Pharma holds royalty rights for products developed by GSK, Biogen, and AbbVie.Some support5 reports
No events began in the chosen period. Widen it, or reset.
What's reaching Royalty Pharma
Events traced to Royalty Pharma, step by step, newest first- Royalty Pharma may gain from strong investor interest in major pharmaRoyalty Pharma may benefit from investor confidence in major pharma holdingsPossible
- Medicare coverage may increase Royalty Pharma's revenue from LeqembiIncreased Medicare coverage may boost Royalty Pharma's revenue from Leqembi.Possible
- Royalty Pharma could gain revenue if AbbVie's ABBV-466 succeedsRoyalty Pharma may benefit from the success of AbbVie's new immunology drugPossible
- Royalty Pharma may benefit from AbbVie's new therapy approvalRoyalty Pharma may see higher revenue from AbbVie's new therapy salesPossible
- Royalty Pharma may gain from AbbVie's market recoveryRoyalty Pharma may benefit from AbbVie's sales recovery after Humira exclusivity lossPossible
- Royalty Pharma may benefit from Zenas's positive obexelimab trial dataRoyalty Pharma may benefit from Zenas's positive obexelimab trial dataPossible
Around Royalty Pharma this week
News at the entities that move Royalty Pharma most-
AbbVie StructuralDHS leans on AbbVie, Altria, and Merck for stock weighting, while the SEC legally requires fiduciaries to prioritize client interests.Moves Royalty Pharma
-
FDA StructuralFDA issued a warning letter to NeoGen regarding a product quality defect on October 7, 2026.Moves Royalty Pharma
-
Amgen StructuralAmgen announced results from the VESALIUS-CV trial, led by Duke and involving Harvard, at AHA's Scientific Sessions.Moves Royalty Pharma
-
Securities and Exchange Commission StructuralAndy Cheung was appointed CFO and Treasurer of The Aaon Group, which subsequently filed a report with the SEC.Moves Royalty Pharma
-
Novartis OperationalBristol-Myers Squibb paused clinical trials following clinical setbacks reported by Novartis.Moves Royalty Pharma
-
GSK StructuralBoth GSK and Galderma operate within the pharmaceutical and biotech sectors.Moves Royalty Pharma
Connections
The 28 strongest of 62, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Pablo Legorreta Structural
Pablo Legorreta is the founder and CEO of Royalty Pharma.
-
AbbVie Structural
Royalty Pharma holds ongoing royalty rights to AbbVie's products, generating revenue from AbbVie's sales.
-
Morgan Stanley Operational
Morgan Stanley actively covers, rates, and invests in Royalty Pharma, linking the two through market analysis and capital allocation.
-
Securities and Exchange Commission Structural
Royalty Pharma must comply with formal regulatory filing requirements set by the SEC.
-
Terry Coyne Structural
Terry Coyne serves as the Chief Financial Officer of Royalty Pharma.
-
FDA Structural
FDA's regulatory decisions and approvals are critical drivers of Royalty Pharma's portfolio value and market perception.
-
Biogen Structural
Royalty Pharma receives payments and holds royalty rights on Biogen's products, supplemented by an ongoing R&D funding partnership.
-
Novartis Operational
Novartis' trial results directly affect Royalty Pharma's investment decisions, which actively tracks Novartis' drug candidates.
Show all 28 connections
-
Theravance Biopharma (United States) Transactional
Theravance expects and receives milestone payments from Royalty Pharma based on financial agreements.
-
Amgen Structural
Royalty Pharma holds royalty rights to Amgen's drugs, establishing a persistent financial dependency on Amgen's sales.
-
Zenas Transactional
Royalty Pharma provided funding to Zenas in exchange for a royalty on sales.
-
SEC Structural
Royalty Pharma operates under the formal oversight and mandatory disclosure requirements of the SEC.
-
GSK Structural
Royalty Pharma holds royalties on GSK's Trelegy, establishing a persistent financial dependency.
-
Thrivent Financial for Lutherans Transactional
Thrivent Financial for Lutherans increased its investment stake in Royalty Pharma.
-
Bank of America Operational
Bank of America actively influences Royalty Pharma's market standing through investment ratings and increasing holdings.
-
Blood Cancer United Operational
The relationship is defined by a collaborative partnership between the two companies.
-
TD Cowen Mentioned together
TD Cowen provides investment ratings and target price increases for Royalty Pharma while disclosing its share holdings.
-
Biotech Structural
Royalty Pharma invests in drug makers and developers, providing financial support to the Biotech sector.
-
AstraZeneca Transactional
Royalty Pharma acquired a royalty interest in AstraZeneca's cliramitug candidate.
-
Tap Transactional
Royalty Pharma is identified as the largest corporate donor to Tap.
-
Citigroup Mentioned together
Citigroup provided a positive financial rating and target price increase for Royalty Pharma.
-
Johnson & Johnson Operational
Royalty Pharma is actively tracking Johnson & Johnson's drug candidates, suggesting strategic interest in their pipeline.
-
MarketBeat Mentioned together
MarketBeat reports on Royalty Pharma's average stock rating and consensus target.
-
Goldman Sachs Transactional
A specific executive from Goldman Sachs was hired for a China team.
-
Nasdaq Shared context
Royalty Pharma is listed on the Nasdaq exchange.
-
Hong Kong Shared context
Royalty Pharma established its first Asia-Pacific base in Hong Kong.
-
Zealand Pharma Transactional
Royalty Pharma provided $100 million in funding to Zealand Pharma.
-
New York City Shared context
Royalty Pharma is headquartered in New York City.
History
Events by the month they beganNovember 2026
1 eventOctober 2026
4 events- Royalty Pharma is investing in drug makers and developers to diversify its portfolio in the biotech sector.
- Royalty Pharma and Aditxt, two healthcare companies, are currently being compared.
- Multiple investment firms acquired, sold, and increased stakes in Royalty Pharma on October 13, 2026.
- Bank of America raised holdings in Royalty Pharma, and Royalty Pharma filed a transaction with the SEC.
September 2026
2 eventsShow 3 earlier months
August 2026
2 eventsJuly 2026
2 eventsJune 2026
14 events- Royalty Pharma acquired a royalty interest in Amgen's drug Imdelltra.
- Visteon filed transaction details with the SEC and traded on the Nasdaq stock exchange on June 6, 2026.
- Pablo Legorreta was named the founder and CEO of Royalty Pharma, which provides funding in exchange for royalty rights.
- Royalty Pharma outperformed the market so far this year, based on data from August 6, 2025.
- Royalty Pharma filed a prospectus with the Securities and Exchange Commission on September 3, 2025.
- Royalty Pharma is headquartered in New York City and opened its first Asia-Pacific base in Hong Kong, while Kenneth Sun moved from Morgan Stanley to the company.
- Trump pledged to unleash American oil and gas, involving Royalty Pharma.
- Kadant, News Corp, Cencora, and Royalty Pharma were identified as high-quality stocks operating in the pharmaceutical industry.
- Buffett described how share prices do not reflect business value, discussing the role of TSR and dividends in the context of Royalty Pharma.
- Royalty Pharma enhanced its governance structure following an acquisition by an external manager.
- Morgan Stanley raised its price target for Royalty Pharma, noting regulatory uncertainty and the impact of tariffs.
- Peter Lynch's advice contrasts with the focus on profitable companies regarding Royalty Pharma.
- Revolution Medicines received Breakthrough Therapy Designation and entered into a major funding agreement, while activating international clinical trials in Europe and Japan.
- Royalty Pharma holds royalty rights for products developed by GSK, Biogen, and AbbVie.